NEPH Nephros
- 2.120
- -0.010-0.47%
Nephros News
Benchmark Reiterates Speculative Buy on Nephros, Maintains $5 Price Target
Benchmark analyst Robert Wasserman reiterates Nephros (NASDAQ:NEPH) with a Speculative Buy and maintains $5 price target.
Earnings Update: Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Are Trimming Their Forecasts
Nephros: Buy Rating Affirmed Amid Solid Performance and Growth Prospects
Nephros Files $50M Mixed Securities Shelf
Nephros Q1 2024 GAAP EPS $(0.02) Beats $(0.04) Estimate, Sales $3.522M Miss $3.734M Estimate
Nephros (NASDAQ:NEPH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 33.33 percent increase over losses of $(0.03) per sha
Nephros | 10-Q: Quarterly report
Nephros Inc to Present Corporate Strategies at Showcase
Nephros to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Nephros, Inc.'s (NASDAQ:NEPH) Profit Outlook
Nephros(NEPH.US) Director Buys US$17,129.7 in Common Stocks
$Nephros(NEPH.US)$ Director Amron Arthur H purchased 7,000 shares of Common Stocks on Mar 12, 2024 at an average price of $2.4471 for a total value of $17,129.7.Source: Announcement What is statement
Nephros Director Arthur Amron Buys $17.1k in Company Stock
US$4.75 - That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After These Results
As you might know, Nephros, Inc. (NASDAQ:NEPH) last week released its latest full-year, and things did not turn out so great for shareholders. Revenues missed expectations somewhat, coming in at
Nephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized Operations
Nephros Price Target Announced at $5.00/Share by Benchmark
Nephros Price Target Announced at $5.00/Share by Benchmark
Nephros Raised to Speculative Buy From Hold by Benchmark
Nephros Raised to Speculative Buy From Hold by Benchmark
Benchmark Upgrades Nephros to Speculative Buy, Announces $5 Price Target
Benchmark analyst Robert Wasserman upgrades Nephros from Hold to Speculative Buy and announces $5 price target.
Nephros Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 70.65% Benchmark → $5 Upgrades Hold → Speculative Buy 01/26/2021 326.62% B. Riley Securities →
Nephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Call Transcript
Nephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy Rating
Earnings Call Summary | Nephros(NEPH.US) Q4 2023 Earnings Conference
The following is a summary of the Nephros, Inc. (NEPH) Q4 2023 Earnings Call Transcript:Financial Performance:Nephros reported a 27% year-over-year increase in Q4 revenue taking it to $3.3 million, an
Analysis
Price Target
No Data
